Scientists test new drug to slow rapid aging in children
NCT ID NCT06775041
Summary
This study is testing a new drug called progerinin in children with Hutchinson-Gilford progeria syndrome, a rare genetic condition that causes rapid aging. All participants will continue taking the current standard drug, lonafarnib, and some will also receive progerinin to see if the combination is safe and to find the best dose. The main goals are to check for side effects and measure how the drug moves through the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUTCHINSON-GILFORD PROGERIA SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.